German pharmaceutical company Boehringer-Ingelheim announced plans yesterday to cut the price of its popular antiretroviral drug nevirapine (Viramune) by 50 percent in low-income countries. However, this lowered price will still be about four times higher than prices of offered by generic manufacturers as part of a recent Clinton Foundation HIV/AIDS initiative.